{"id":80588,"date":"2024-11-21T19:26:42","date_gmt":"2024-11-21T18:26:42","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?post_type=customer-stories&#038;p=80588"},"modified":"2026-05-13T10:01:36","modified_gmt":"2026-05-13T08:01:36","slug":"site-training-soars-at-bayer-with-veeva-study-training","status":"publish","type":"customer-stories","link":"https:\/\/pantheon.veeva.com\/eu\/customer-stories\/site-training-soars-at-bayer-with-veeva-study-training\/","title":{"rendered":"Bayer"},"content":{"rendered":"<style>\n.cus-story, .cus-story p, .cus-story ul li, .cus-story ol li {\n    font-family: \"Roboto\", sans-serif;\n    font-weight: 300;\n    font-size: 18px;\n    line-height: 26px;\n    text-transform: unset;\n    margin-bottom: 20px;\n    margin-top: 15px;\n    color: #444;\n}<\/p>\n<p>.img-right {\n    float: right;\n    width: 40%;\n    margin: 20px 0 20px 40px;\n}<\/p>\n<p>@media screen and (max-width: 991px) {\n .img-right  {\nfloat: none;\nwidth: 100%;\nmax-width: 400px;\nmargin: 0;\nmargin-top: 10px;\ndisplay: block;\nmargin-left: auto;\nmargin-right: auto;\n}\n}\n<\/style>\n<p>\nBiopharma companies face a long-standing industry challenge of training<br \/>\nstudy staff and site personnel in an efficient, cost-effective, and compliant<br \/>\nway. Site staffing requirements are some of the most <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3092661\/\" target=\"_blank\" rel=\"noopener noreferrer\">expensive components of a clinical research program<\/a>, so streamlining training to minimize risk is vital<br \/>\nfor sponsors\u2019 bottom line.\n<\/p>\n<p>\nEllen Vanderlinden, global clinical capability strategy lead at Bayer, is on a<br \/>\nmission to enable both internal study teams and site staff to produce the<br \/>\nhigh-quality training compliance data needed for the company to support<br \/>\nthe delivery of therapeutic products. \u201c<a href=\"\/eu\/products\/veeva-study-training\/\">Veeva Study Training<\/a> really is<br \/>\nour foundation to support electronic study site training documentation,\u201d<br \/>\nVanderlinden explains. \u201cWe have the end-to-end compliant solution that<br \/>\nwe were looking for.\u201d\n<\/p>\n<h2>Nowhere to scale<\/h2>\n<p>\nThe increasing volume and complexity in clinical studies make it challenging for<br \/>\nsponsors to manage training assignments and records manually. Compliance<br \/>\nerrors are more likely without a connected system that enables study teams to<br \/>\noversee assignment completion and automate training documentation.\n<\/p>\n<p>\nFor years, Vanderlinden\u2019s team relied on costly external vendors for study-specific<br \/>\ntraining, which focused on face-to-face training in a one-size-fits-all model.<br \/>\nVanderlinden recalls the typical approach: \u201cTraining site staff came at a high cost<br \/>\nfor us as a sponsor. We were transporting doctors from around the world to a<br \/>\ncentral location for them to spend entire days in meeting rooms, presenting slide<br \/>\nafter slide. This didn\u2019t consider the knowledge, experience, and the specific role of<br \/>\neach member of staff in the study.\u201d\n<\/p>\n<p>\nClinical research associates (CRAs) would often have to repeat training for site<br \/>\nstaff that could not join the live session. They also relied on wet ink paper sign-off<br \/>\nof training documentation. \u201cIt was very resource intensive for sites and sponsors,\u201d<br \/>\nsays Vanderlinden. \u201cUltimately, this approach gave us no oversight nor further<br \/>\nunderstanding of how the training was received and objectives understood.\u201d\n<\/p>\n<p>\nSpurred by the COVID-19 pandemic, Vanderlinden\u2019s team brought the electronic training documentation solution in-house and worked to scale up with a non-validated internal system. A benefit of this approach was that learners could complete training online without having to travel offsite. But many manual<br \/>\nprocesses were still required for the study teams to produce compliant<br \/>\ndocumentation: from disconnected Excel trackers and SharePoint files to<br \/>\npaper logs to track training. After manual sign-off, it would be filed to their<br \/>\nVeeva Vault eTMF.\n<\/p>\n<h2>Enabling sites through targeted training<\/h2>\n<p>\nVanderlinden is an advocate for site needs and is focused on improving the study-<br \/>\nspecific training available to them. She had two key objectives when devising a<br \/>\nnew study training strategy:<\/p>\n<ol>\n<li>Meet the needs of individual sites and studies<\/li>\n<li>Implement a simple, efficient, and user-friendly platform<\/li>\n<\/ol>\n<p>\n\u201cI\u2019m very mindful of the fact that site staff need to spend most of their time with<br \/>\npatients,\u201d Vanderlinden says. \u201cAs sponsors, we should ask ourselves: \u2018How can we<br \/>\nbe more targeted in the training we deliver and our expected outcomes?\u2019\u201d\n<\/p>\n<blockquote><p>\n&#8220;Veeva Study Training really is our foundation to support electronic study site training documentation.&#8221;<br \/>\n<span> &#8211; Ellen Vanderlinden, Global Clinical Capability Strategy Lead, Bayer<\/span>\n<\/p><\/blockquote>\n<p>\nVanderlinden sought an automated, end-to-end training process in a validated<br \/>\nsystem with these objectives in mind. Bayer became an early adopter of Veeva<br \/>\nStudy Training, which enables companies to automate and streamline training<br \/>\nfor sponsors, CROs, and sites in one system. Vanderlinden\u2019s team introduced<br \/>\nthe system in 2022 and implemented a multi-method approach to study training,<br \/>\noffering recorded training modules and pre-requisite reading of key study<br \/>\ndocumentation, as well as targeted virtual and face-to-face interactions where<br \/>\nthere is additional study complexity.\n<\/p>\n<p>\nBayer currently has 42 ongoing studies using Veeva Study Training across 50<br \/>\ncountries. Of those, 11 are using the platform for site staff training, which includes<br \/>\nabout 10,000 users from 1,000 sites across 37 countries.\n<\/p>\n<p>\n\u201cOne of the key criteria for us to work with Veeva was that it\u2019s an easy-to-use<br \/>\nsystem,\u201d explains Vanderlinden. \u201cOn a practical level, we can leverage our<br \/>\nconnections with the Veeva Clinical Platform. We use the training material, site staff<br \/>\ninformation, and site readiness status stored within the Clinical Vault. This was a<br \/>\nkey opportunity we saw for implementing Veeva Study Training.\u201d\n<\/p>\n<p>\nA centralized team is responsible for logistics, set-up, and back-end support,<br \/>\nand that same team managed the migration of select records from the existing<br \/>\ninternal system. \u201cFor us, the centralized team worked very well,\u201d says Vanderlinden.<br \/>\nShe adds: \u201cWe wanted to ensure a consistent approach to migration and avoid<br \/>\nburdening the study teams.\u201d<\/p>\n<blockquote><p>\n&#8220;We use the training material, site staff information, and site readiness status that\u2019s stored within the Veeva Clinical Platform. This was a key opportunity we saw for implementing Veeva Study Training.&#8221;<br \/>\n<span> &#8211; Ellen Vanderlinden, Global Clinical Capability Strategy Lead, Bayer<\/span>\n<\/p><\/blockquote>\n<h2>From time-consuming to<br \/>\njust-in-time<\/h2>\n<p>\nAs well as benefiting sites, Veeva Study Training has<br \/>\nchanged how Bayer\u2019s study teams plan, deliver, and<br \/>\nmonitor training. They now automatically assign training<br \/>\nby role and geographical location using the training<br \/>\nmatrix builder featured in the system. Study teams can<br \/>\ncreate training curricula for each study in their portfolio,<br \/>\nwhether it\u2019s protocol-specific training using documents<br \/>\nin Veeva eTMF or non-protocol-specific training, such<br \/>\nas Good Clinical Practice (GCP). Veeva Study Training uses the matrix<br \/>\nto automatically facilitate training to the relevant study<br \/>\npersonnel. \u201cVeeva really worked magic by getting the<br \/>\ntraining matrix builder into the system,\u201d says Vanderlinden.\n<\/p>\n<p>\nThe outcome is the ability to deliver just-in-time training,<br \/>\nfocusing on what each role needs to know, and when, in<br \/>\norder to properly treat patients.\n<\/p>\n<blockquote><p>\n\u201cVeeva really worked magic by getting the training matrix builder into the system.&#8221;<br \/>\n<span> &#8211; Ellen Vanderlinden, Global Clinical Capability Strategy Lead, Bayer<\/span>\n<\/p><\/blockquote>\n<p><img decoding=\"async\" class=\"img-right w-40\" alt=\"\" src=\"\/wp-content\/uploads\/2024\/11\/Bayer-eTMF-Case-Study-Img-1.png\"><\/p>\n<p>\nVanderlinden\u2019s team collected feedback from sites and<br \/>\ndiscovered that most sites begin thinking about training<br \/>\nabout four weeks before they are ready to enroll. \u201cWe want<br \/>\nthem to be able to focus during this time on training,\u201d says<br \/>\nVanderlinden, adding: \u201cThis is where Vault Study Training<br \/>\nis facilitating that just-in-time approach.\u201d\n<\/p>\n<p>\nAnother manual process alleviated by Veeva Study Training<br \/>\nis managing study documentation. Veeva Study Training<br \/>\nconnects to Vault eTMF to eliminate the need to manually<br \/>\ncapture study and site information. \u201cWe see Veeva Study<br \/>\nTraining as a vehicle to support our process from the start<br \/>\nof how to deliver training up until getting documentation in<br \/>\nVeeva eTMF,\u201d explains Vanderlinden. \u201cThe auto-filing back<br \/>\nto Veeva eTMF will close the loop, giving us a compliant<br \/>\nway to have that oversight.\u201d\n<\/p>\n<h2>A high-quality system for all<\/h2>\n<p>\nA study training platform must meet the needs of several<br \/>\nkey stakeholders: it should be easy to use for learners,<br \/>\nsimple to track learner progress for CRAs, and be a reliable<br \/>\ntool for sponsors. Vanderlinden was confident in the Veeva<br \/>\nStudy Training platform, particularly as it is built on a<br \/>\nmature learning management system. But she was keen<br \/>\nto find out whether the Veeva Study Training platform was<br \/>\nmeeting other stakeholders\u2019 needs. They shared that they<br \/>\nbenefit from using VeevaID, which is a login unique to<br \/>\neach site user that enables them to access all their<br \/>\nVeeva systems.\n<\/p>\n<p>\n\u201cThey really like the fact that it\u2019s one system for various<br \/>\nstudies, and that it\u2019s easy to access. They saw the benefit<br \/>\nwith the onboarding of new staff throughout the study as<br \/>\nwell.\u201d Based on this feedback, Vanderlinden estimates an<br \/>\nalmost 100 percent adoption rate of Veeva Study Training<br \/>\namong sites.\n<\/p>\n<p>\nThe increased oversight that the platform provides, along<br \/>\nwith automated reporting and dashboards, are favorite<br \/>\nfeatures among CRAs. Vanderlinden describes the<br \/>\nreaction from her internal team: \u201cWe\u2019ve decreased the<br \/>\nlearning curve for CRAs to work with the system and<br \/>\naccelerated the study start-up process.\u201d\n<\/p>\n<h2>Continuing training evolution<\/h2>\n<p>\nReflecting on her team\u2019s journey with Veeva Study Training,<br \/>\nVanderlinden highlights their collaboration with Veeva as<br \/>\na crucial factor for success. \u201cIt\u2019s been unbelievably great.<br \/>\nThere has always been an open conversation, with us<br \/>\nbouncing ideas off of each other,\u201d she says.\n<\/p>\n<p>\nLooking ahead, Bayer will continue to increase its<br \/>\nautomation of study training and expand its use of the<br \/>\nsystem to more sites. Vanderlinden is also planning to evolve<br \/>\nhow training is assigned: \u201cI\u2019m particularly excited about the<br \/>\nresponsibility aspect of task-based training. In the future, we<br \/>\nwant principal investigators to be able to assign task-based<br \/>\ntraining, to further tailor it for each individual.\u201d\n<\/p>\n<p>\n<a href=\"\/eu\/customer-stories\/site-training-soars-at-bayer-with-vault-study-training\/\">Learn<\/a> more about how Vanderlinden\u2019s team uses Veeva Study Training to enable an automated, end-to-end process in a validated system.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer evolves study-specific training with an automated, end-to-end system that delivers tailored curricula.<\/p>\n","protected":false},"featured_media":66773,"parent":0,"template":"","product-link-list":[1394],"class_list":["post-80588","customer-stories","type-customer-stories","status-publish","has-post-thumbnail","hentry","product-link-list-veeva-clinical-platform"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/customer-stories\/80588"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/customer-stories"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/types\/customer-stories"}],"version-history":[{"count":2,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/customer-stories\/80588\/revisions"}],"predecessor-version":[{"id":97046,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/customer-stories\/80588\/revisions\/97046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media\/66773"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=80588"}],"wp:term":[{"taxonomy":"product-link-list","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/product-link-list?post=80588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}